DNLI
Denali Therapeutics Inc.
NASDAQ · Healthcare · Biotechnology · US
$22.28
−2.28%Margins
Gross margin
-61.0%
EBITDA margin
—
EBIT margin
—
Net margin
—
FCF margin
—
-61.2%
Return on equity
-44.2%
Return on assets
-62.9%
Return on invested capital
0.00x
Asset turnover
-$434.0M
Cash from operations
$4.44
Cash per share
Margins, returns on capital and operating efficiency from the latest trailing period · Data as of Jun 1, 2026